Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study

doi:10.3748/wjg.v26.i38.5874

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 38

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5025)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

225

WORD

162

HTML

2263

Figures (1-3)

277

Tables (1-2)

174

Sum=3101

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

714

Download

1210

Sum=1924

Oct 14, 2020 (publication date) through Jun 5, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Oct 14, 2020; 26(38): 5874-5883
Published online Oct 14, 2020. doi: 10.3748/wjg.v26.i38.5874

Open in New Tab Full Size Figure Download Figure

Figure 1 Flowchart of patients visited in the Opioid Treatment Program and hepatitis C virus infection status. OTP: Opioid Treatment Program; HCV: Hepatitis C virus; DAAs: Direct antiviral agents.

Open in New Tab Full Size Figure Download Figure

Figure 2 Annual rates of hepatitis C virus treatment with direct antiviral agents in an Opioid Treatment Program. p-y: Person-years.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan Meier estimates (95%CI) of direct antiviral agent treatment for hepatitis C virus. Plots included (A) all patients and (B) patients with hepatitis C virus (HCV) mono-infection and HCV-human immunodeficiency virus co-infection. HIV: Human immunodeficiency virus; DAAs: Direct antiviral agents.

Citation: Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Majó X, Colom J, Muga R. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol 2020; 26(38): 5874-5883
URL: https://www.wjgnet.com/1007-9327/full/v26/i38/5874.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i38.5874